We expect Collagen Solutions’ ChondroMimetic regenerative medicine scaffold for the treatment of damaged cartilage in the knee to be approved during 2017. While taking a conservative view on revenues at this time, we estimate that the total market potential for this product in Europe is €400m. At more reasonable market penetration rates we believe ChrondroMimetic revenues could deliver significant upside versus our current forecasts.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ChondroMimetic potential
- Published:
14 Feb 2017 -
Author:
Chris Donnellan -
Pages:
26
We expect Collagen Solutions’ ChondroMimetic regenerative medicine scaffold for the treatment of damaged cartilage in the knee to be approved during 2017. While taking a conservative view on revenues at this time, we estimate that the total market potential for this product in Europe is €400m. At more reasonable market penetration rates we believe ChrondroMimetic revenues could deliver significant upside versus our current forecasts.